How quickly can tetrabenazine be titrated in an inpatient psychiatric hospital?

Tetrabenazine Titration in Inpatient Psychiatric Settings

In an inpatient psychiatric hospital, tetrabenazine should be titrated by 12.5 mg per week, starting at 12.5 mg daily, with close monitoring for adverse effects including depression, parkinsonism, and sedation. 1

Standard Titration Protocol

The FDA-approved titration schedule for tetrabenazine follows a structured weekly approach 1:

• Starting dose: 12.5 mg once daily in the morning
• Week 1: Continue 12.5 mg daily
• Week 2: Increase to 25 mg daily (12.5 mg twice daily)
• Subsequent weeks: Increase by 12.5 mg per week as tolerated

Maximum single dose: 25 mg (for doses ≤50 mg/day, given in divided doses twice daily)

For doses above 50 mg/day, the medication should be divided into three times daily dosing, with a maximum single dose of 37.5 mg in extensive metabolizers 1.

Critical Monitoring During Titration

The inpatient setting offers advantages for rapid titration, but several adverse effects require vigilant monitoring:

Psychiatric Adverse Effects

• Depression and suicidality: This is a boxed warning concern. If depression emerges during titration, stop dose escalation immediately and consider reducing the dose or discontinuing treatment 1
• Monitor daily for mood changes, particularly during the first 2-4 weeks of titration

Motor Adverse Effects

• Parkinsonism and akathisia: These dose-dependent effects may emerge during titration 1
• If extrapyramidal symptoms occur, halt titration and reduce the dose
• Do not use anticholinergics (like benztropine) to manage these symptoms—instead, reduce the tetrabenazine dose

Sedation

• Dose-dependent sedation is common and may limit titration speed 1
• Consider timing doses to minimize functional impairment

Inpatient-Specific Considerations

The controlled inpatient environment allows for:

1. Daily assessment: Unlike outpatient titration, you can evaluate response and tolerability daily
2. Faster identification of adverse effects: Nursing staff can monitor for emerging depression, sedation, or motor symptoms continuously
3. Immediate dose adjustments: If adverse effects occur, doses can be reduced same-day rather than waiting for follow-up appointments

However, the standard weekly titration intervals should still be maintained 1. The clinical trial that established tetrabenazine's efficacy used a 7-week titration period to reach therapeutic doses 1, and more rapid titration increases the risk of intolerable adverse effects.

Practical Titration Algorithm

Week 1-2: Start 12.5 mg daily, assess for tolerability

• If sedation is problematic, give at bedtime
• Monitor mood daily

Week 3-4: Increase to 25 mg daily (divided twice daily)

• Continue daily psychiatric and motor assessments
• If depression or parkinsonism emerges, hold at current dose or reduce

Week 5+: Continue weekly increases of 12.5 mg

• Titrate until chorea is adequately controlled, adverse effects occur, or maximum dose is reached
• For doses >50 mg/day, switch to three times daily dosing

Dosing Above 50 mg/Day

CYP2D6 genotyping is required before exceeding 50 mg/day 1. This is a regulatory requirement, not merely a recommendation:

• Extensive/intermediate metabolizers: Can titrate up to 100 mg/day (maximum single dose 37.5 mg)
• Poor metabolizers: Maximum total daily dose is 50 mg (maximum single dose 25 mg)
• Patients on strong CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine): Treat as poor metabolizers—do not exceed 50 mg/day total 1

Common Pitfalls

1. Titrating too rapidly: The weekly interval exists to allow identification of tolerable doses before adverse effects become severe
2. Ignoring psychiatric symptoms: Depression can emerge insidiously—daily mood assessment is essential
3. Using anticholinergics for EPS: This masks the problem rather than solving it; reduce tetrabenazine instead
4. Exceeding 50 mg/day without genotyping: This violates FDA labeling and increases risk of adverse effects 1

Treatment Interruption

If treatment is interrupted for >5 days, retitration from the starting dose is required 1. For interruptions <5 days, the previous maintenance dose can be resumed without retitration. This is relevant in the inpatient setting where medication refusal or medical complications may interrupt therapy.

Evidence Base

The pivotal trial 2 used a 7-week titration period with weekly 12.5 mg increases, reaching a mean dose of approximately 50 mg/day. This titration schedule balanced efficacy (3.5-point reduction in chorea score) against tolerability, with 91% of patients completing the study. More aggressive titration was not studied and would likely increase the 9% discontinuation rate seen in the trial 1.